EUCTR2007-007787-25-IT进行中（未招募）不适用
se of subconjunctival Bevacizumab (Avastin) in treatment of corneal neovascularization non curable with standard protocols (topical and sistemic steroids). - ND
AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA0 个研究点开始时间: 2008年1月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients of either sex.
- •3.Afflicted with corneal neovascularization resulting from corneal pathology (trauma, burn, caustication, keratitis e.g. Herpetic, pemphigus or ocular pemphigoid, neovascularization of corneal transplantation), non responding to topical treatment and such that to reduce significantly visual function and/or jeopardize new corneal transplantation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Recent thrombo-embolic or ischemic occurrences (last 6 months).
- •2.Systemic hypertension not treated or not adequately controlled by therapy.
- •3.Pregnancy
研究者
相似试验
已完成
不适用
Intravitreal Bevacizumab (Avastin) therapy for Proliferative Diabetic Retinopathydiabetic retinopathy.Retinal disorders in diseases classified elsewhereIRCT138903314232N1Vice chancellor for research; Babol university of medical sciences39
已完成
不适用
Assessment of subconjunctival bevacizumab effect on the postoperative healing course and recurrence of excised pterygiumpterygium.corneal degenerationIRCT138805192326N1Vice-chancellery of Research Affairs of Shiraz University of Medical Sciences32
尚未招募
不适用
The response of intravitreal bevacizumab in the treatment of intraocular neovascularizatioOcular neovascularizationJPRN-UMIN000009389Osaka University Hospital80
尚未招募
不适用
The response of intravitreal bevacizumab in the treatment of macular edemamacular edemaJPRN-UMIN000009390Osaka University Hospital180
尚未招募
2 期
Role of subconjunctival injection of Bevacizumab (Anti VEGF) for Corneal Neovascularisation,after cornea TransplantCTRI/2021/10/037416SNMedical College